Ubiquitination of, and sumoylation by, the Arf tumor suppressor

Israel Medical Association Journal

Volumn 8, Issue 4, 2006, Pages 249-251

  den Besten, Willem ^a   Kuo, Mei Ling ^a   Tago, Kenji ^a   Williams, Richard T ^a   Sherr, Charles J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Arf induced sumoylation; Cancer; Ink4a Arf locus; N terminal ubiquitination; Nucleophosmin (NPM B23); Tumor suppression

Indexed keywords

ACID PROTEIN; ARF PROTEIN; NUCLEOPHOSMIN; PROTEASOME; PROTEIN MDM2; PROTEIN P16INK4A; PROTEIN P19; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE E3;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; CELLULAR DISTRIBUTION; ENZYME ACTIVITY; GENE LOCUS; GENETIC CODE; HUMAN; MOLECULAR INTERACTION; MOLECULAR MECHANICS; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN STABILITY; PROTEIN TARGETING; PROTEIN TRANSPORT; REGULATORY MECHANISM; UBIQUITINATION;

CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; HUMANS; LEUKEMIA, MYELOID; NUCLEAR PROTEINS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN;

EID: 33646066826     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995;83:993-1000.
2. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002;2:103-12.
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
4. Sherr CJ. Principles of tumor suppression. Cell 2004;116:235-46.
5. ARF act in overlapping pathways in cellular immortalization. Nat Cell Biol 2000;2:148-55.
6. ARF tumor suppressor. Genes Dev 2000;14:2358-65.
7. McKeller RN, Fowler JL, Cunningham JJ, et al. The Arf tumor suppressor gene promotes hyaloid vascular regression during mouse eye development. Proc Natl Acad Sci USA 2002;99:3848-53.
8. ARF. Cell 1997;91:649-59.
9. Kamijo T, Bodner S, van de Kamp E, Randle DH, Sherr CJ. Tumor spectrum in ARF-deficient mice. Cancer Res 1999;59:2217-22.
10. Zindy F, Williams RT, Baudino TA, et al. Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proc Natl Acad Sci USA 2003;100:15930-5.
11. Kuo M-L, den Besten W, Bertwistle D, Roussel MF, Sherr CJ. N-terminal polyubiquitination and degradation of the Arf tumor suppressor. Genes Dev 2004;18:1862-74.
12. Bloom J, Amador V, Bartolini F, DeMartino G, Pagano M. Proteasome-mediated degradation of p21 via N-terminal ubiquitinylation. Cell 2003;115:71-82.
13. Polevoda B, Sherman F. N-terminal acetyltransferases and sequence requirements for N-terminal acetylation of eukaryotic proteins. J Mol Biol 2003;325:595-622.
14. a-acetyl transferase families. Trends Biochem Sci 1998;23:263-7.
15. Itahana K, Bhat KP, Jin A, et al. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosomal biogenesis and cell proliferation. Mol Cell 2003;12:1151-64.
16. Bertwistle D, Sugimoto M, Sherr CJ. Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol Cell Biol 2004;24:985-96.
17. Korgaonkar C, Hagan J, Tompkins V, et al. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol Cell Biol 2005;25:1258-71.
18. Xirodimas DP, Chisholm J, Desterro JMS, Lane DP, Hay RT. p14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2. FEBS Lett 2002;528:207-11.
19. Chen L, Chen J. MDM2-ARF complex regulates p53 sumoylation. Oncogene 2003;22:5348-57.
20. Tago K, Chiocca S, Sherr CJ. Sumoylation induced by the Arf tumor suppressor: A p53-independent function. Proc Nat Acad Sci USA 2005;102:7689-94.
21. Johnson ES. Protein modification by SUMO. Annu Rev Biochem 2004;73:355-82.
22. Hilgarth RS, Murphy LA, Skaggs HS, Wilkerson DC, Xing H, Sarge KD. Regulation and function of SUMO modification. J Biol Chem 2004;279:53899-902.
23. Boggio R, Colombo R, Hay RT, Draetta GF, Chiocca S. A mechanism for inhibiting the SUMO pathway. Mol Cell 2004;16:549-61.
24. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005;352:254-66.
25. Cazzaniga G, Dell'Oro MG, Mecucci C, et al. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood 2005;106:1419-22.
26. Nakagawa M, Kameoka Y Suzuki R. Nucleophosmin in acute myelogenous leukemia. N Engl J Med 2005;352:1819-20.
27. den Besten W, Kuo M-L, Williams RT, Sherr CJ. Myeloid leukemia-associated nucleophosmin mutants perturb p53-dependent and independent activities of the Arf tumor suppressor protein. Cell Cycle 2005;4:1593-8.